Inhibition of neoplastic growth by N-homocysteine thiolactonyl retinamido cobalamin.
Because of the importance of homocysteine thiolactone metabolism in the growth of normal tissues, and because of abnormal metabolism of homocysteine thiolactone in malignant cells, N-substituted derivatives of homocysteine thiolactone were synthesized and assayed for antineoplastic and anticarcinogenic activities. A single dose of 2.5 mg/kg of the synthetic derivative, N-homocysteine thiolactonyl retinamido cobalamin, injected directly into subcutaneous human pancreatic adenocarcinoma neoplasms in athymic mice, caused 50% inhibition of growth without evidence of toxicity. The findings suggest a novel approach to counteracting the growth of malignant neoplasms and support the hypothesis of a deficiency of an N-homocysteine thiolactonyl derivative in malignant cells.